Kornimate/medical-research-clean huggingface dataset:
neuroendocrine and adrenal tumors

Conditions: Neuroendocrine Tumors; Adrenal Tumor

Summary: this is a prospective study of rare neuroendocrine and adrenal tumors. subjects will be enrolled via informed consent, and blood and/or saliva and tissue will be collected. this is designed to work in conjunction with irb#831990 which is a retrospective protocol. the university of pennsylvania will be a contributing site with the university of michigan as the coordinating site for the a5 alliance, a multi-institutional collaborative designed to study neuroendocrine and adrenal tumors.


Eligibility criteria:
inclusion criteria: * diagnosed with neuroendocrine and/or an adrenal tumor exclusion criteria: * pregnant women * prisoners * people under the age of 18
safety study of scio-469 to treat patients with active rheumatoid arthritis receiving methotrexate

Conditions: Rheumatoid Arthritis

Summary: the main objective of the study is to evaluate the safety and tolerability of six escalating doses of scio-469 in ra patients. scio-469 belongs to a new class of treatments that inhibit p38 kinase, a stimulatory modulator of pro-inflammatory factors including tumor necrosis factor-alpha (tnf-alpha), interleukin-1 (il-1), and cyclooxygenase-2 (cox-2), all of which are known to contribute to both symptoms and disease progression in patients with rheumatoid arthritis.

this multicenter, randomized, double-blind, placebo-controlled, dose-escalating study will assess the safety, tolerability, efficacy, pk and pharmacodynamics of scio-469 in patients with active ra who also are receiving methotrexate. a total of 120 subjects will be randomly assigned and treated in one of seven dose groups with the total daily dose of scio-469 ranging from 0 to 180 mg. dose groups will be staggered over four treatment periods. safety and available pk data from a treatment period with lower dose groups will be reviewed prior to initiating higher dose groups in the next treatment period. placebo subjects will be randomized in all treatment periods. study drug will be taken for 30 days. each subject will be followed for approximately 4 weeks after completing the 30-day treatment period. safety will be assessed by way of physical examination, medical history, vital signs, orthostatic vital signs, chest radiograph, 12-lead electrocardiogram (ecg), clinical laboratory evaluations (including serum chemistry, hematology, qualitative urinalysis, and liver function tests), purified protein derivative test for tuberculosis, neurological tests, adverse events, and concomitant medications through out the study. study drug will be administered for 30 days at one of the following dosage strengths; 30 mg, 60 mg, 90 mg. one group of subjects will get 60 mg for one week followed by 120 for one week followed by 180 mg for two weeks.

Eligibility criteria:
inclusion criteria: * patients who have active rheumatoid arthritis and are receiving methotrexate * meet the revised 1987 american rheumatism association (ara) criteria for rheumatoid arthritis * has active ra as demonstrated by 9 tender and 6 swollen joints and one of the following: c-reactive protein 1.0 mg/dl, erythrocyte sedimentation rate (esr) 28 mm/hour, or morning stiffness = 45 minutes. . exclusion criteria: * patient used etanercept, infliximab, anakinra, or an experimental biologic agent within past 3 months * had elevation of liver enzymes within past 6 months * has a history of tuberculosis * vertigo, inner ear, or vestibular abnormalities * cancer * hiv-positive * abnormal electrocardiogram * patient has chronic or acute infection * multiple sclerosis, neuropathy or encephalopathy

Keywords: rheumatoid arthritis scio-469
survival after emergency laparotomy in octogenarians

Conditions: Abdomen, Acute; Surgery--Complications; Postoperative Complications; Frailty

Summary: in this single-center retrospective study we wanted to investigate mortality and postoperative complications after emergency laparotomy performed in patients aged 80 years or above.

methods: during 2015-2016 106 patients aged 80 years or above underwent emergency laparotomy at haukeland university hospital. primary outcome was mortality at 30 days. secondary outcomes were mortality at 90 days, 1 year, postoperative complications and level of care at discharge. the medical records were reviewed in detail and mortality and postoperative morbidity were registered. post-operative complications were defined according to the european perioperative clinical outcome (epco) definitions and included if they were clavien dindo grade 2 or above.

Eligibility criteria:
inclusion criteria: * emergency laparotomy in patients 80 years or above exclusion criteria: * palliative surgery * abdominal surgery other than gastrointestinal * abdominal surgery without midline incision

Keywords: emergency surgery frailty elderly postoperative complications
screening to predict weight loss in patients with cancer

Conditions: Cachexia; Gastrointestinal Cancer; Hematopoietic/Lymphoid Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: screening tests may identify people with cancer who are at high risk of losing weight and help doctors plan better treatment. purpose: this clinical trial is studying how well a new screening tool works in predicting weight loss in patients with cancer.

objectives: * to identify people with cancer who are at greatest risk of future weight loss by the development of a simple and practical screening tool. * to estimate the reliability of the appetite and symptom questionnaire (part 1). * to develop a screening tool based on the ability of the optimal combination of items from the three measures (asq, must, crp) to predict clinically significant weight loss over three months (part 2). * to estimate the sensitivity and specificity at various cut-points of the developed screening tool in predicting clinically significant weight loss (\> 10% weight loss or between 5% and 10% weight loss with a bmi \< 20 kg/m\^2) over three months (part 2). outline: this is a two-part study. * part 1: patients are asked to complete the appetite and symptom questionnaire (asq) on two occasions, one week apart. * part 2: patients are screened at baseline for risk of malnutrition using the malnutrition universal screening tool. blood samples are also taken at this time to establish the level of c-reactive protein and patients complete the asq. patients are weighed using calibrated scales and height measurements are obtained. patients are asked about unplanned weight loss over the previous 3-6 months. patients are weighed again at 3 months. percentage weight loss is calculated at 3 months.

Eligibility criteria:
disease characteristics: * meets 1 of the following criteria, depending on part of study: * part 1: * receiving radiotherapy for cancer at nottingham city hospital * likely to be clinically stable over the duration of one week (i.e., not at high risk of disease or treatment-related appetite and weight loss) * stable weight and appetite * part 2: * outpatient at nottingham city hospital with a confirmed diagnosis of primary lung or gastrointestinal cancer * lost no more than 10% of pre-illness stable body weight * lost no more than 5% of pre-illness stable body weight if body mass index (bmi) was less than 20 kg/m\^2 * bmi ≥ 18.5 kg/m\^2 patient characteristics: * no condition impairing the ability to swallow * not receiving enteral tube feeding or parenteral nutrition (part 2) * able to be weighed (part 2) prior concurrent therapy: * see disease characteristics * no concurrent radiotherapy to the head, neck or upper gastrointestinal tract area

Keywords: cachexia lung cancer gastrointestinal cancer unspecified adult solid tumor, protocol specific hematopoietic/lymphoid cancer
doxercalciferol in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases

Summary: rationale: doxercalciferol may improve low blood cell counts and decrease the need for blood transfusions and may be an effective treatment for myelodysplastic syndrome or chronic myelomonocytic leukemia. purpose: phase ii trial to study the effectiveness of doxercalciferol in treating patients who have myelodysplastic syndrome or chronic myelomonocytic leukemia.

objectives: * determine the response rate of patients with myelodysplastic syndromes or chronic myelomonocytic leukemia treated with doxercalciferol. * determine the toxicity profile of this drug in these patients. * determine the time to progression and overall survival of patients treated with this drug. outline: patients receive oral doxercalciferol daily for 12 weeks. treatment continues in the absence of disease progression or unacceptable toxicity. projected accrual: approximately 41 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * morphologically and cytogenetically confirmed myelodysplastic syndromes or chronic myelomonocytic leukemia * no more than 20% blasts by bone marrow biopsy * must meet at least 1 of the following criteria: * anemia * hemoglobin less than 11 g/dl over a 2-month period * thrombocytopenia * neutropenia patient characteristics: age * 18 and over performance status * ecog 0-2 life expectancy * not specified hematopoietic * see disease characteristics hepatic * alt and ast less than 1.5 times upper limit of normal * bilirubin less than 3 mg/dl * albumin greater than 3.0 g/dl renal * creatinine clearance greater than 50 ml/min * no history of hypercalcemia * no renal stones within the past 5 years cardiovascular * no clinically significant heart failure * no uncontrolled hypertension pulmonary * no clinically significant pulmonary failure other * not pregnant * fertile patients must use effective contraception during and for 6 months after study prior concurrent therapy: biologic therapy * at least 4 weeks since prior growth factor or cytokine therapy chemotherapy * at least 8 weeks since prior cytotoxic chemotherapy endocrine therapy * not specified radiotherapy * not specified surgery * not specified other * concurrent transfusion support allowed

Keywords: chronic myelomonocytic leukemia previously treated myelodysplastic syndromes secondary myelodysplastic syndromes de novo myelodysplastic syndromes atypical chronic myeloid leukemia myelodysplastic/myeloproliferative disease, unclassifiable
acellular dermal matrix in primary palatoplasty

Conditions: Cleft Palate

Summary: the goal of the present study is to definitely determine whether the use of acellular dermal matrix (adm) during primary cleft palate repair decreases the rate of fistula formation. although individual studies have described promising advantages to its use in cleft palate surgery, no consensus currently exists. without concrete evidence, one must question the whether the increased cost, time and potential patient risk (human derived tissue) to patients justifies its use in primary cleft palate repair.

there has been a change in the standard practice at the montreal children's hospital where the senior author has shifted from selected application of adm in certain cases to routine use of adm in all cleft palate cases. this study is an observational study comparing a prospective cohort group receiving adm routinely to a retrospective historical cohort group without routine use of adm. objectives of the study: primary objectives: the primary objective of this study is to determine whether routine use of adm would lower the incidence of palatal fistula in patients undergoing primary cleft palate repair. secondary objectives: 1. incidence of wound dehiscence 2. incidence of wound infection 3. hospital length of stay

Eligibility criteria:
inclusion criteria: * children diagnosed as having veau class ii to iv cleft palates undergoing furlow palatoplasty with adm between the ages of 3 months and 3 years will be included in this study. exclusion criteria: * selection will be based on the parent's willingness to allow their child to participate in the study. * children with diagnosed craniofacial syndromes will be excluded from the study due their higher than usual incidence of palatal fistulas. * children with known wound healing defects, such as ehler danlos syndrome, pseudoxanthoma elasticum, will be excluded from the study due to their inherent collagen defects and consequently on the incidence of palatal fistulas. * children with veau class i cleft palates and those who will need/needed any surgical technique other then furlow palatoplasty will be excluded from the study.

Keywords: palatoplasty acellular dermal matrix
overcoming barriers in vision care utilization of african americans with diabetes

Conditions: Diabetic Retinopathy; Diabetes Mellitus

Summary: the goal of this project is to implement a collaborative translational research center (trc) network study which aims to assure optimal two-way communication between ophthalmologists and their patients' primary care physicians (pcp). the collaborative trc network study will have 2 objectives: * to design and develop common research protocols to develop a 4-year retrospective database (2007-2010) that compiles electronic billing and medical chart information that can be used to study individual-level, clinical-level and system-level factors that impact access to and quality of vision care; * to evaluate adherence to dilated fundus exams (dfes) follow-up as the primary measureable quality indicator, and its relationship to the patients' demographics, ethnicity, socioeconomic status (ses), severity of diabetic retinopathy (dr), other ocular and medical co-morbidities, presence of ha1c, and primary care provider (pcp) communication. by enhancing communication and strengthening the clinical information exchanged between pcps and eye care professionals, this collaborative trc network study will help to overcome barriers to obtaining ongoing dfes and reduce disparities in vision care utilization.

since its inception in october 2010 collaborative network research study at the wills eye institute has aimed: 1. to establish a retrospective analysis of existing ophthalmic data sets to assess and evaluate system-level and individual-level factors that impact access to and quality of vision care in patients with diabetes; 2. to implement telephone-based and educational interventions to improve dfe follow-up adherence in african americans with diabetes utilizing a prospective, cluster-based, randomized cohort design; 3. to determine the feasibility and effectiveness of using a non-invasive, non-mydriatic fundus camera (nidek) in a community-based pharmacy setting to screen and detect diabetic retinopathy and other ocular diseases among individuals with diabetes.

Eligibility criteria:
inclusion criteria for aim 1: 1. age ≥ 18 years 2. type 2 diabetes mellitus 3. had a dilated fundus exam (dfe) within the past four years (2007-2010). exclusion criteria for aim 1: 1) pregnant women inclusion criteria for aim 2 and 3: 1. age ≥ 18 years 2. type 2 diabetes mellitus 3. access to a telephone

Keywords: eye care utilization ophthalmology educational intervention public health screening
effectiveness of the addition of the kinesio taping method to conventional physical therapy treatment in patients with chronic nonspecific low back pain

Conditions: Nonspecific Chronic Low Back Pain

Summary: the purpose of this study is to determine the effectiveness of the addition of the use of kinesio taping in patients with chronic nonspecific low back pain who receive conventional physical therapy.

one hundred and forty-eight patients will be randomized to receive either conventional physical therapy, which consist of a combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization (conventional physical therapy group) or to receive conventional physical therapy plus the addition of the kinesio taping in the lumbar spine (conventional physical therapy plus kinesio taping), over a period of 5 weeks (10 sessions of treatment). clinical outcomes (pain intensity, disability and global perceived effect ) will be collected at baseline and at 5 weeks, 3 and 6 months after randomization. data will be collected by a blinded examiner who will be unaware about the group allocation. all statistical analysis will be conducted following the principles of intention to treat analysis and the between-group differences will be performed using mixed linear models.

Eligibility criteria:
inclusion criteria: * patients with non-specific low back pain longer than 12 weeks * seeking care for low back pain exclusion criteria: * contra indications to physical exercise * serious spinal pathologies (e.g. tumors, fractures and inflammatory diseases) * nerve root compromise * contra indications to the kinesio taping (e.g. intolerance to tapes, band aids etc) * pregnancy * severe cardiorespiratory conditions

Keywords: back pain tape chronic
long term follow-up for hypospadias

Conditions: Hypospadias

Summary: hypospadias is a frequent malformation. the definition of hypospadias is a ventral tissues hypoplasia, with an abnormal position of the urethral meatus, a chordee of the penis and an open foreskin. it can be associate with other genital malformation; in that case it can be classified in the wider field of the disorder of sex development (dsd). there is a lot of surgical technics for those malformations. in the pediatric surgical department, in lyon, three technics are the most used because of their reliability and their good outcomes in short and mid term. this is essential for investigator to have a long term evaluation, with a physical exam and paraclinical exams, after the puberty, to assess the outcomes after the changes especially at the puberty.


Eligibility criteria:
inclusion criteria: * male patients * with previous hypospadias surgery, * birthday before december the 31th 2009. * the surgery was performed by one operator, with the following surgical technics: koff, onlay and koyanagi. * the patients are informed by an official surgery department letter, to assure they agree to participate. * if the patient is still an infant, the parental agreement will be necessary. exclusion criteria: * patient deceased * non- agreement from the patient or his parents * language difficulties
diu-qol. quality of life evaluation in intrauterine device users.

Conditions: Contraception

Summary: knowledge about the impact on quality of life of women initiating iud in the spanish population at baseline and after 12 months of use.


Eligibility criteria:
inclusion criteria: * 18-49 years old female. * women who is visited by a gynecology or primary care physician and starts contraception with an iud/ius. * women that has not used hormonal contraception in any form in the last 3 months. * women who have no problems listening, reading or writing. * women who gives their written consent to participate in the study. exclusion criteria: * women who have contraindications to use iuds. * women with previous experience with iuds. * women who initiates the use of iuds for other purposes other than contraception. * woman who is participating in a clinical trial at the time of initiating the study.

Keywords: hrqol iud contraception sec-qol
effect of telerehabilitation practice in long covid-19 patients

Conditions: Long COVID-19; Long COVID; Post COVID-19 Condition; Post-COVID-19 Syndrome; Post-COVID Syndrome

Summary: the goal of this clinical trial is to test the efficacy of telerehabilitation practice in long covid-19 patients. the main question\[s\] it aims to answer are whether telerehabilitation practice in long covid-19 patients help to reduce stress oxidative, reduce inflammation, improve functional capacity and improve quality of life. participants will receive 12 weeks of telerehabilitation practice researchers will compare intervention group (that received telerehabilitation) and control group (that received standard treatment) to see if there is better outcome in intervention group.

study background: several study show that some survivors of covid-19 have post covid-19 sequelae. previous studies suggest that rehabilitation interventions with appropriate prescription of physical exercise can provide short, medium and long term health benefits. telerehabilitation services are an innovative strategy to support rehabilitation intervention and hopefully able to increase compliance of patients to exercise program. this study aims to prove the effectiveness of telerehabilitation in improving levels of inflammation, oxidative stress, functional capacity and quality of life in long covid-19 patients. participants will be divided into intervention group and control group. baseline measurement will be taken. telerehabilitation will be given to the intervention group for 12 weeks. control group will receive standard rehabilitation treatment. after 12 weeks post intervention measurement will be taken.

Eligibility criteria:
inclusion criteria: * covid-19 survivors * have at least one of the following sequelae: * fatigue * dyspnea and/or chronic cough * joint and/or muscle pain * headache * insomnia (difficulty sleeping) * impaired concentration / memory * willing to take part in the telerehabilitation program regularly during the study * willing to participate in the research and sign the consent form exclusion criteria: * unable to use the mobile phone application and zoom meet * unable to come to the hospital for examination or training (if needed) * cognitive impairment (mmse \<21) * neuromusculoskeletal disorder which will affect rehabilitation interventions * severe chronic lung disease * severe heart disease (grade iii-iv from the new york heart association) * chronic kidney disorders * malignancy * severe autoimmune disease

Keywords: long covid-19 telerehabilitation rehabilitation exercise